

Stimuli-Responsive Nanomedicine: Pharmacological Insights and Pharmaceutical Applications

Dorendra Deshmukh¹, Yashika², Gitanjali Kashyap², Priyanka Raj³, Neha Mandle^{4*}

¹Maitri College of Pharmacy, Anjora, Durg, Chhattisgarh, 491001.

²Kamla Institute of Pharmaceutical Sciences, Bhilai, Chhattisgarh, 490020.

³DBM College of Pharmacy, Devraha, Champa, Chhattisgarh, 495671.

⁴Shri Shankaracharya College of Pharmaceutical Sciences, Bhilai, Chhattisgarh, 490020.

*Corresponding Author E-mail: nehamandle1996@gmail.com

Abstract:

Stimuli-responsive nanomedicine represents a transformative leap in drug delivery — enabling site-specific, on-demand, and controlled drug release in response to physiological or externally applied triggers. By responding to cues such as pH, temperature, redox potential, enzymes, magnetic fields, or light, these “smart” nanocarriers significantly enhance therapeutic efficacy while minimizing systemic toxicity. This review outlines the fundamental pharmacological principles underlying stimuli-responsive systems, their material composition, mechanisms of action, and applications in cancer therapy, inflammation, infection control, and regenerative medicine. Furthermore, we discuss design strategies, challenges in clinical translation, and emerging hybrid nanoplatforms integrating multiple stimuli for precision therapy.

Keywords: Stimuli-Responsive Nanocarriers, Smart Drug Delivery, Ph-Sensitive Nanoparticles, Redox-Responsive Systems, Targeted Therapy, Controlled Release, Nanomedicine.

Received: Jan. 21, 2026

Revised: Feb. 28, 2026

Accepted: March. 28, 2026

Published: April 12, 2025

DOI: <https://doi.org/10.64474/3107-6726.Vol2.Issue1.7>

<https://jepmr.nknpub.com/1/issue/archive>

This is an Open Access article distributed under the terms of the Creative Commons Attribution (CC BY NC), which permits unrestricted use, distribution, and reproduction in any medium, as long as the original authors and source are cited. No permission is required from the authors or the publishers. (<https://creativecommons.org/licenses/by-nc/4.0/>)

1. Introduction

Conventional drug delivery systems are often limited by poor specificity, suboptimal pharmacokinetics, and systemic side effects, which can compromise therapeutic efficacy and patient safety¹⁻². Stimuli-responsive nanomedicine has emerged as a next-generation strategy that addresses these challenges by enabling precise, on-demand drug release in response to specific physiological or external cues. In particular, the tumor microenvironment (TME) offers a rich landscape of internal triggers — such as acidic pH, elevated levels of reducing agents like glutathione (GSH), and overexpressed enzymes — which can be exploited to design smart nanocarriers that selectively release therapeutic payloads at disease sites. Beyond endogenous triggers, external stimuli such as temperature, light, ultrasound, and magnetic fields allow clinicians to remotely control drug activation, providing an additional layer of precision⁴⁻⁵. Together, these approaches enhance drug bioavailability, minimize off-target toxicity, and enable real-time modulation of therapeutic responses, representing a transformative advancement in precision pharmacology⁶.

2. Classification of Stimuli-Responsive Nanocarriers


Stimuli-responsive nanocarriers can be broadly categorized based on the nature of the triggering signal into internal (endogenous) and external (exogenous) systems. Endogenous triggers capitalize on the unique pathophysiological features of diseased tissues, such as the acidic microenvironment of tumors, overexpressed enzymes, hypoxia, or redox imbalances, to induce drug release selectively at the target site⁷⁻⁸. (Table 1) In contrast, exogenous triggers rely on externally applied stimuli — including temperature, light, ultrasound, or magnetic fields — which allow clinicians to spatially and temporally control the activation of the nanocarrier system. This dual categorization provides a versatile framework for designing sophisticated, site-specific drug delivery platforms that can adapt to complex biological environments and therapeutic demands⁹⁻¹⁰. (Figure 1)

Table 1. Classification of Stimuli-Responsive Nanocarriers

Type	Trigger	Example Mechanism	Typical Application	Reference
Internal	pH, enzymes, redox, ROS	pH-dependent polymer swelling, enzyme cleavage	Cancer, infection, inflammation	11

External	Temperature, magnetic field, ultrasound, light	Thermal phase change, magneto-mechanical heating	Hyperthermia, phototherapy, localized release	12
----------	--	--	---	----

Figure 1. Schematic Overview of Stimuli-Responsive Mechanisms



3. Materials and Design Principles

The development of stimuli-responsive nanomedicines relies on the careful selection of materials that undergo predictable physicochemical changes in response to specific internal or external cues¹³⁻¹⁴. Among the most widely studied are pH-responsive systems, which exploit acid-labile linkages such as hydrazone, acetal, or imine bonds that cleave under mildly acidic conditions (pH 5–6). Polymers like poly(L-histidine), chitosan, and poly(β -amino esters) are commonly employed, making these systems particularly suitable for targeting acidic environments such as tumors or endosomal compartments¹⁵⁻¹⁶.

Redox-responsive nanocarriers utilize the elevated intracellular concentrations of reducing agents like glutathione (GSH) to trigger drug release. Incorporation of disulfide (-S-S-) or diselenide linkages ensures that the drug payload is released selectively within the cytosol,

minimizing off-target effects¹⁷⁻¹⁸. Enzyme-responsive systems achieve specificity by including enzyme-sensitive peptide or polymer substrates that degrade in the presence of pathological enzymes such as matrix metalloproteinases (MMPs) or hyaluronidase, thereby providing precise activation within diseased tissues.

Thermo-responsive systems employ polymers such as poly(N-isopropylacrylamide) (PNIPAM), which exhibit a lower critical solution temperature (LCST). Above this temperature, the polymer collapses and expels the encapsulated drug, enabling controlled release during hyperthermia-based therapies. In addition, magnetic and light-responsive systems allow external control over drug delivery¹⁹⁻²⁰. Magnetic nanoparticles, such as Fe₃O₄, can be guided or heated using external magnetic fields, whereas light-responsive carriers utilize photo-cleavable bonds or plasmonic heating from gold nanoshells to trigger site-specific release. Collectively, these design principles form the foundation for creating versatile, smart nanocarriers capable of precise, stimuli-directed therapeutic action²¹⁻²².

4. Pharmacological Mechanisms of Stimuli Responsiveness

From a pharmacological perspective, stimuli-responsive nanomedicines are designed to precisely modulate drug release kinetics, cellular uptake, and overall biodistribution, thereby optimizing therapeutic efficacy while minimizing off-target effects. One of the primary advantages of these systems is controlled drug release. By responding to specific internal or external triggers, such as pH, redox potential, temperature, or enzymes, these nanocarriers can maintain a near zero-order release profile, preventing the peak–trough fluctuations often associated with conventional formulations and ensuring a steady therapeutic concentration over time²³⁻²⁴.

In addition to precise release kinetics, stimuli-responsive systems significantly enhance bioavailability. Targeted activation at the site of disease reduces premature degradation or hepatic clearance, allowing a higher proportion of the administered dose to reach the intended tissue. This is particularly beneficial in cases where conventional systemic delivery results in subtherapeutic exposure at the target site²⁵⁻²⁶.

Another critical pharmacological benefit is reduced systemic toxicity. By restricting drug release to pathological environments—such as the acidic or enzyme-rich tumor microenvironment—these systems limit drug exposure to healthy tissues, thereby reducing adverse effects. This selective activation is especially advantageous in cancer chemotherapy, where conventional cytotoxic drugs often damage rapidly dividing normal cells²⁷⁻²⁸.

Finally, advanced stimuli-responsive nanocarriers increasingly utilize multi-stimuli integration, combining two or more triggers (e.g., pH + redox, magnetic + thermal) to achieve even higher specificity and control²⁹⁻³⁰. This multi-modal approach allows precise

spatiotemporal drug release, adaptive dosing in response to changing microenvironmental conditions, and enhanced therapeutic outcomes. By integrating pharmacological principles with smart material design, stimuli-responsive systems represent a paradigm shift in precision medicine, offering a level of control and efficacy unattainable with traditional drug delivery approaches³¹⁻³². Table 2

Table 2. Examples of Pharmacological Stimuli and Mechanistic Effects

Stimulus	Pharmacological Effect	Representative Carrier	Model Drug	Reference
pH	Endosomal-triggered release	Poly(β -amino ester) NP	Doxorubicin	33
Redox	GSH-mediated cleavage	Disulfide-linked micelle	Paclitaxel	34
Enzyme	MMP-responsive hydrogel	Peptide-polymer conjugate	Cisplatin	35
Light	Photothermal heating	Gold nanoshell	Curcumin	36
Magnetic	Localized heating	Fe ₃ O ₄ -liposome hybrid	5-FU	37

5. Pharmaceutical Applications

Stimuli-responsive nanomedicines have demonstrated transformative potential across multiple therapeutic areas, offering precise, controlled, and site-specific drug delivery. In oncology, these systems exploit the unique characteristics of the tumor microenvironment—such as acidity, hypoxia, and elevated redox gradients—to achieve selective drug release³⁸. For instance, pH-sensitive liposomes are engineered to release chemotherapeutics like doxorubicin preferentially in acidic tumor tissues, enhancing local drug accumulation while minimizing systemic exposure. Similarly, redox-responsive micelles utilize high intracellular glutathione (GSH) levels in tumor cells to trigger paclitaxel release, ensuring that cytotoxic activity is confined to malignant tissues. Such targeted strategies not only improve therapeutic efficacy but also significantly reduce adverse effects commonly associated with conventional chemotherapy³⁹⁻⁴⁰.

In the realm of infectious diseases, enzyme-sensitive nanoparticles provide a precision approach to antibiotic delivery. For example, β -lactamase-responsive nanocarriers release antibacterial agents specifically in infected tissues, thereby maximizing local drug concentration and simultaneously reducing systemic exposure. This targeted activation minimizes selective pressure on commensal bacteria, helping to curb the emergence of antibiotic resistance⁴¹⁻⁴².

For inflammatory disorders, stimuli-responsive systems are designed to release anti-inflammatory drugs in response to oxidative stress or elevated enzymatic activity within affected tissues. Reactive oxygen species (ROS) - and enzyme-responsive carriers, for instance, can deliver corticosteroids like dexamethasone directly to inflamed joints in arthritis or to the colonic mucosa in colitis, improving therapeutic outcomes while limiting systemic immunosuppression⁴³⁻⁴⁴.

In neurological and cardiovascular applications, external stimuli-responsive nanocarriers are employed to enhance localized delivery. Magnetic or ultrasound-responsive systems can transiently open the blood–brain barrier (BBB) or facilitate targeted drug accumulation in ischemic myocardium, allowing precise treatment of conditions such as stroke or myocardial infarction. By combining endogenous and exogenous triggers, these systems enable spatiotemporally controlled therapy, overcoming the pharmacokinetic limitations of conventional drug administration⁴⁴⁻⁴⁵. Overall, stimuli-responsive nanomedicine represents a versatile platform that aligns pharmacological precision with advanced pharmaceutical engineering, enabling safer and more effective interventions across diverse clinical settings⁴⁶⁻⁴⁷. Table 3

Table 3. Stimuli-Responsive Nanocarriers in Clinical Development

System	Stimulus	Target Indication	Clinical Stage	Reference
ThermoDox® (liposome)	Temperature	Liver cancer	Phase III	48
Ferumoxytol®	Magnetic	Anemia / Imaging	FDA-approved	49
NanoCurc®	pH-sensitive	Colon cancer	Phase II	50
Redox-micelle (experimental)	Redox	Breast cancer	Preclinical	51

6. Challenges and Limitations


Despite impressive advances in stimuli-responsive nanomedicine at the laboratory and preclinical levels, translating these systems into clinical practice remains challenging. One major hurdle is reproducibility and scale-up; nanocarrier synthesis protocols must consistently produce uniform particle sizes, surface characteristics, and predictable responsiveness during large-scale manufacturing. Minor variations in fabrication can significantly affect drug release profiles and therapeutic outcomes⁵². Another key challenge lies in biological complexity.

Endogenous stimuli such as pH, redox potential, or enzymatic activity vary not only between patients but also across tissues and pathological states, complicating precise prediction of in vivo release kinetics. Additionally, toxicity and immunogenicity are critical concerns. Long-term accumulation of certain inorganic components, such as gold or iron oxide nanoparticles, may pose biocompatibility issues, while surface modifications intended to enhance targeting can inadvertently trigger immune responses⁵³⁻⁵⁴. Finally, regulatory barriers impede clinical translation. Stimuli-responsive systems often straddle the boundary between drug and device, creating ambiguity in regulatory classification and prolonging the approval process for human use. Collectively, these challenges highlight the need for standardized manufacturing practices, rigorous safety evaluation, and integrated regulatory strategies⁵⁵⁻⁵⁶.

7. Emerging Trends and Future Perspectives

Looking ahead, several emerging trends are poised to accelerate the development and clinical adoption of stimuli-responsive nanomedicine. AI-driven nanocarrier design is becoming a powerful tool, allowing researchers to predict responsiveness, optimize polymer composition, and model drug release kinetics using machine learning algorithms trained on extensive experimental datasets. Multi-stimuli hybrid platforms are also gaining traction; by integrating triggers such as pH, redox potential, temperature, or light within a single carrier, these systems offer unprecedented precision in complex in vivo environments⁵⁷⁻⁵⁸. Theranostic nanomedicine represents another frontier, combining therapeutic payloads with imaging agents (e.g., MRI or fluorescent markers) to enable real-time tracking of drug release and therapeutic response. Finally, the adoption of biodegradable and green nanomaterials—including polylactic acid, silk fibroin, and other eco-friendly polymers—is driving sustainable development, reducing long-term toxicity risks while addressing environmental concerns. Collectively, these innovations promise to overcome current limitations, paving the way for clinically viable, precise, and patient-tailored stimuli-responsive therapies⁵⁹⁻⁶⁰. (Figure 2)

Figure 2. Future Directions in Smart Nanomedicine



8. Conclusion

Stimuli-responsive nanomedicine represents a transformative approach in modern pharmacology, offering a level of precision and control unattainable with conventional drug delivery systems. By harnessing endogenous cues—such as pH variations, redox gradients, and disease-specific enzyme activity—or exogenous triggers like temperature, light, and magnetic fields, these smart nanocarriers achieve targeted, on-demand drug release at pathological sites. This strategy not only maximizes therapeutic efficacy but also minimizes systemic toxicity, a critical advantage in oncology, infectious diseases, inflammatory disorders, and neurological applications. While clinical translation faces challenges related to reproducibility, biological complexity, long-term safety, and regulatory classification, ongoing innovations in biodegradable materials, multi-stimuli hybrid platforms, AI-guided design, and theranostic integration are steadily bridging the gap from bench to bedside. Ultimately, stimuli-responsive nanomedicine exemplifies the future of precision therapeutics, combining intelligent delivery with patient-tailored treatment strategies to enhance outcomes and redefine standards of care.

References

1. Carvalho-de-Souza, J. L., Treger, J. S., Dang, B., Kent, S. B. H., Pepperberg, D. R., & Bezanilla, F. (2015). *Neuron*, 86(1), 207.
2. Wu, Y., Ali, M. R. K., Chen, K. C., Fang, N., & El-Sayed, M. A. (2019). *Nano Today*, 24, 120.
3. Paviolo, C., & Stoddart, P. R. (2017). *Nanomaterials*, 7(4), 92.
4. Lee, N., Yoo, D., Ling, D., Cho, M. H., Hyeon, T., & Cheon, J. (2015). *Chemical Reviews*, 115(19), 10637.
5. Hu, G., & He, B. (2012). *Applied Physics Letters*, 100(3), 031901.
6. Funnell, J. L., Ziemba, A. M., Nowak, J. F., Awada, H., Prokopiou, N., Samuel, J., Guari, Y., Nottelet, B., & Gilbert, R. J. (2021). *Acta Biomaterialia*, 131, 302–314.
7. Dubey, D., Christiansen, M. G., Vizovisek, M., Gebhardt, S., Feike, J., & Schuerle, S. (2022). *Small*, 18(12), 2201325.
8. Viard, M., & Puri, A. (2015). In A. Iglic, C. V. Kulkarni, & M. Rappolt (Eds.), *Advances in planar lipid bilayers and liposomes* (Vol. 22, pp. 1–41). Elsevier Academic Press.
9. Joglekar, M., & Trewyn, B. G. (2013). *Biotechnology Journal*, 8(8), 931.
10. Taghizadeh, B., Taranejoo, S., Monemian, S. A., Moghaddam, Z. S., Daliri, K., Derakhshankhah, H., & Derakhshani, Z. (2015). *Drug Delivery*, 22(2), 145.
11. Yeingst, T. J., Helton, A. M., Rawnaque, F. S., Arrizabalaga, J. H., Ravnic, D. J., Simon, J. C., & Hayes, D. J. (2025). *Gels*, 11(1), 120.
12. Ibrahim, M., Sabouni, R., Husseini, G. A., Karami, A., Bai, R. G., & Mukhopadhyay, D. (2020). *Journal of Biomedical Nanotechnology*, 16(9), 1359.

13. Wang, Z. Y., He, X. X., Chen, S. Y., He, C. D., Wang, T., & Mao, X. (2021). *International Journal of Molecular Sciences*, 22(17), 9457.
14. Stewart, E., Kobayashi, N. R., Higgins, M. J., Quigley, A. F., Jamali, S., Molton, S. E., Kapsa, R. M., Wallace, G. G., & Crook, J. M. (2015). *Tissue Engineering Part C: Methods*, 21(4), 385.
15. Quigley, A. F., Bulluss, K. J., Kyratzis, I. L. B., Gilmore, K., Mysore, T., Schirmer, K. S. U., Kennedy, E. L., O'Shea, M., Truong, Y. B., Edwards, S. L., Peeters, G., Herwig, P., Razal, J. M., Campbell, T. E., Lowes, K. N., Higgins, M. J., Molton, S. E., Murphy, M. A., Cook, M. J., ... Kapsa, R. M. I. (2013). *Journal of Neural Engineering*, 10(1), 016008.
16. Lu, Q., Jang, H. S., Han, W. J., Lee, J. H., & Choi, H. J. (2019). *Macromolecular Research*, 27(11), 1061.
17. Patil, T. V., Patel, D. K., Dutta, S. D., Ganguly, K., & Lim, K. T. (2021). *Molecules*, 26(19), 5738.
18. Xue, J. L., Gao, Z. S., & Xiao, L. Y. (2019). *Frontiers in Chemistry*, 7, 6.
19. Negri, V., Pacheco-Torres, J., Calle, D., & López-Larrubia, P. (2020). *Topics in Current Chemistry*, 378(41), 1–20.
20. Vila, M., Cicuéndez, M., Sánchez-Marcos, J., Fal-Miyar, V., Manzano, M., Prieto, C., & Vallet-Regí, M. (2013). *Journal of Biomedical Materials Research Part A*, 101(1), 213–223.*
21. Víg, L., Zátunyi, A., Csernyus, B., Horváth, A. C., Bojtár, M., Kele, P., Madarász, M., Rózsa, B., Fürjes, P., Hermann, P., Hakkel, O., Péter, L., & Fekete, Z. (2024). *Sensors*, 24(22), 6897.*
22. Armenia, I., Ayllón, C. C., Herrero, B. T., Bussolari, F., Alfranca, G., Grazú, V., & de la Fuente, J. M. (2022). *Advanced Drug Delivery Reviews*, 191, 114584.
23. Rapoport, N. (2016). In J. M. Escoffre & A. Bouakaz (Eds.), *Therapeutic ultrasound* (pp. 221–250). Springer International Publishing.
24. Esrafilzadeh, D., Razal, J. M., Molton, S. E., Stewart, E. M., & Wallace, G. G. (2013). *Journal of Controlled Release*, 169(4), 313–320.
25. Burgess, A., & Hynynen, K. (2014). *Expert Opinion on Drug Delivery*, 11(5), 711.
26. Sharma, G., Sharma, A. R., Lee, S. S., Bhattacharya, M., Nam, J. S., & Chakraborty, C. (2019). *International Journal of Pharmaceutics*, 559, 360–372.
27. Tang, Z. M., Ye, F. X., Ni, N., Fan, X. Q., Lu, L. N., & Gu, P. (2025). *Journal of Nanobiotechnology*, 23(50), 1–14.
28. Quigley, A. F., Razal, J. M., Thompson, B. C., Molton, S. E., Kita, M., Kennedy, E. L., Clark, G. M., Wallace, G. G., & Kapsa, R. M. I. (2009). *Advanced Materials*, 21(43), 4393–4397.
29. Burnstine-Townley, A., Eshel, Y., & Amdursky, N. (2020). *Advanced Functional Materials*, 30(27), 2000345.
30. Arami, H., & Krishnan, K. M. (2013). *IEEE Transactions on Magnetics*, 49(7), 3500.

31. Lindner, J. R. (2004). *Nature Reviews Drug Discovery*, 3(6), 527.
32. Klibanov, A. L. (2009). *Medical & Biological Engineering & Computing*, 47(8), 875.
33. Allen, J. S., May, D. J., & Ferrara, K. W. (2002). *Ultrasound in Medicine & Biology*, 28(6), 805.
34. Klibanov, A. L. (2021). *Investigative Radiology*, 56(1), 50.
35. Fedorova, A. A., Levin, O. V., Eliseeva, S. N., Katrašnik, T., & Anishchenko, D. V. (2023). *International Journal of Molecular Sciences*, 24(9406), 1–15.*
36. Marques-Almeida, T., Ribeiro, C., Irastorza, I., Miranda-Azpiazu, P., Torres-Alemán, I., Silvan, U., & Lanceros-Méndez, S. (2023). *ACS Applied Materials & Interfaces*, 15(31), 31206.
37. Da Silva, A. C., Wang, J., & Minev, I. R. (2022). *Nature Communications*, 13, 1353.
38. Jain, A., Jobson, I., Griffin, M., Rahman, R., Smith, S., & Rawson, F. J. (2022). *Bioelectronic Medicine*, 8(1), 17.
39. Stepulane, A., Ahlgren, K., Rodriguez-Palomo, A., Rajasekharan, A. K., & Andersson, M. (2023). *Colloids and Surfaces B: Biointerfaces*, 226, 113304.
40. Hou, Z.-L., Ma, X., Zhang, J., Li, C., Wang, Y., & Cao, M. (2022). *Small*, 18(24), 2205624.
41. Yiming, B., Hubert, S., Cartier, A., Bresson, B., Mello, G., Ringuede, A., & Creton, C. (2025). *Nature Communications*, 16, 431.
42. Kim, Y., Park, C., Im, S., & Kim, J. H. (2020). *Scientific Reports*, 10, 16488.
43. Dijk, G., Pas, J., Markovic, K., Scancar, J., & O'Connor, R. P. (2023). *APL Bioengineering*, 7(4), 046117.
44. Zhang, T., Chen, S., Petkov, P. S., Zhang, P., Qi, H., Nguyen, N. N., Zhang, W., Yoon, J., Li, P., Brumme, T., Alfonso, A., Liao, Z., Hambsch, M., Xu, S., Mester, L., Kataev, V., Büchner, B., Mannsfeld, S. C. B., Zschech, E., ... Feng, X. (2025). *Nature*, 638(7814), 411.
45. Liang, Y., Mitriashkin, A., Lim, T. T., & Goh, J. C.-H. (2021). *Biomaterials*, 276, 121008.
46. Zhao, L. J., Zhang, H., Tang, N., Li, M. H., & Hu, J. (2023). *ACS Applied Materials & Interfaces*, 15(41), 41927.
47. Zhou, C., Wang, C., Xu, K., Niu, Z., Zou, S., Zhang, D., Qian, Z., Liao, J., & Xie, J. (2023). *Bioactive Materials*, 25, 615.
48. Huang, S. H., Hong, X. Q., Zhao, M. Y., Liu, N. B., Liu, H. L., Zhao, J., Shao, L. Q., Xue, W., Zhang, H., Zhu, P., & Guo, R. (2022). *Bioengineering & Translational Medicine*, 7(3), e1030.
49. Mendes, A. X., do Nascimento, A. T., Duchi, S., Quigley, A. F., Caballero Aguilar, L. M., Dekiwadia, C., Kapsa, R. M. I., Silva, S. M., & Molton, S. E. (2023). *Journal of Materials Chemistry B*, 11(4), 581.
50. Mendes, A. X., Silva, S. M., O'Connell, C. D., Duchi, S., Quigley, A. F., Kapsa, R. M. I., & Molton, S. E. (2021). *ACS Biomaterials Science & Engineering*, 7(8), 2279.

51. Thamilselvan, G., David, H., Sajeevan, A., Rajaramon, S., Solomon, A. P., Durai, R. D., & Narayanan, V. H. B. (2023). *Scientific Reports*, 13, 11373.
52. do Nascimento, A. T., Mendes, A. X., Begeng, J. M., Duchi, S., Stoddart, P. R., Quigley, A. F., Kapsa, R. M. I., Ibbotson, M. R., Silva, S. M., & Molton, S. E. (2023). *Biomaterials Science*, 11, 5146.
53. Fu, Q., Yu, W., Bao, G., & Ge, J. (2022). *Nature Communications*, 13, 7007.
54. Wang, S., Yu, L., Wang, S., Zhang, L., Chen, L., Xu, X., Song, Z., Liu, H., & Chen, C. (2022). *Nature Communications*, 13, 3408.
55. Chong, J., Sung, C., Nam, K. S., Kang, T., Kim, H., Lee, H., Park, H., Park, S., & Kang, J. (2023). *Nature Communications*, 14, 2206.
56. Ji, D., Park, J. M., Oh, M. S., Nguyen, T. L., Shin, H., Kim, J. S., Kim, D., Park, H. S., & Kim, J. (2022). *Nature Communications*, 13, 3019.
57. Duc, D., Stoddart, P. R., McArthur, S. L., Kapsa, R. M. I., Quigley, A. F., Boyd-Moss, M., & Molton, S. E. (2019). *Advanced Healthcare Materials*, 8(18), 1801321.
58. Yang, X., Liang, X., Nandi, R., Tian, Y., Zhang, Y., Li, Y., Zhou, J., Dong, Y., Liu, D., Zhong, Z., & Yang, Z. (2022). *Biosensors*, 12(275), 1–12.
59. Zhang, J., Liu, Y., & Wu, P. (2024). *Nature Communications*, 15, 8920.
60. Beigmohammadi, M., Sadigh, M. K., & Poursamad, J. (2024). *Scientific Reports*, 14, 5756.